Temoporfin

Drug Profile

Temoporfin

Alternative Names: EF 9; Foscan; KW 2345; m-THPC; meta-Tetrahydroxyphenyl chlorin

Latest Information Update: 15 Feb 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator QuantaNova
  • Developer biolitec; University of Salzburg
  • Class Antineoplastics; Mesoporphyrins
  • Mechanism of Action Photosensitisers; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Head and neck cancer
  • Phase II Basal cell cancer; Cholangiocarcinoma; Lipoma; Prostate cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Oct 2008 Kirin Pharma Company has merged with Kyowa Hakko to form Kyowa Hakko Kirin
  • 17 Mar 2003 A study has been added to the Cancer therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top